The effects of a series of caprolactam derivatives with central depressant, convulsant or muscle relaxant activity were investigated upon y-aminobutyric acid (GABA) receptor-ionophore binding to rat brain membranes u~ing Some caprolactams produced a picrotoxin-like chloride-dependent partial inhibition of muscimol binding and were potent inhibitors of TBPS binding. One compound that was further investigated (4,4,6,6-tetramethylhexahydro-2H-azepin-2-one), inhibited GABA responses and increased the frequency of paroxysmal depolarizations in cultured neurones. Other caprolactams enhanced muscimol binding and were relatively weak inhibitors of TBPS binding, and one (3,3-diallyl-6,6-dimethylhexahydro-2H-azepin-2,4-dione) was shown to enhance GABA responses and produced quiescence of activity in cultured neurones. There was a direct correlation between caprolactam effects on muscimol binding in the presence of chloride ions and their effects on TBPS binding suggesting a similar site of action for the caprolactams influencing the binding of these two ligands. For the two classes of caprolactams, with respect to inhibition or enhancement of muscimol binding, there appeared to be a relationship between in vitro effects and their convulsant or depressant activity in mice. Caprolactams may be useful low molecular weight probes for the study of GABA receptor-ionophore complexes.
INTRODUCTION
A large number of sedative or convulsant drugs contain a substituted lactam system. Examples include drugs with 5-(phenytoin, ethosuximide), 6-(barbiturates, glutarimides, primidone and methyprylon) and 7-membered ring systems (various benzodiazepines). Caprolactam (hexahydro-2H-azepin-2-one), the simplest 7-membered ring lactam has convulsant activity in high doses 3. This activity was found to be increased by alkylation (especially methylation) at various positions, in particular at carbons 4 and 6 of the lactam ring2, 5. Some other caprolactams, however, such as those with large alkyl substituents at carbon 7 have sedative activity in miceL
There iselectrophysiological evidence to suggest that the convulsant caprolactams may be acting as ~-aminobutyric acid (GABA) antagonists 7. Little, however, is known about the mode of GABA antagonism by these caprolactams. GABA antagonists may be grouped into two main classes: (1) those acting upon the GABA recognition site, such as bicuculline; and (2) those blocking GABA-activated chloride ion fluxes at GABA receptor coupled chloride channels, e.g. picrotoxin (reviewed in Johnston et al. 6 ) and tert.-butylbicyclophosphorothionate (TBPS) 19 . Recently, incubation conditions have been identified whereby both bicuculline-like and picrotoxin-like agents may affect in vitro GABA binding to brain membrane preparations 21. In the presence of physiological concentrations of chloride ions and at room temperature or above, picrotoxin and related convulsants produced a potent but partial inhibition of GABA binding to rat brain membranes. In contrast, both agonists and antagonists at the GABA recognition site fully inhibited binding either in the presence or absence of chloride ions 4. Several groups have demonstrated a chloride-dependent enhancement of GABA receptor binding by barbituratesl,11A3,ts, 21,22, 23. [35S]TBPS has been introduced recently as a ligand with which to study specific sites coupled to GABA and chloride recognition sites 19 . A wide variety of drugs likely to interact with GABA receptor-ionophore complexes have been shown to inhibit TBPS binding 19, whereas benzodiazepine agonists enhance TBPS binding20.
In the present experiments, the effects of pentobarbitone, picrotoxinin and several caprolactam derivatives with convulsant, sedative or muscle relaxant activity in mice, were examined upon the binding of radiolabelled GABA, muscimol and TBPS to rat brain membranes. The effects of two caprolactams were further examined upon spontaneous electrical activity and responses to iontophoretically applied GABA in mouse spinal cord neurones in dissociated cell culture. It is reported that various caprolactam derivatives can modulate GABA receptor binding and GABA responses in vitro, most probably at the level of GABA receptor-coupled chloride channels.
MATERIALS AND METHODS
Washed synaptosomal membranes were prepared from whole rat brains as previously describedlT, is. Briefly, whole brains of male Sprague-Dawley rats (10-12 weeks old) were homogenized in 0.32 M sucrose and a P2 synaptosomal-mitochondrial pellet formed by differential centrifugation. This pellet was lysed in distilled water, and washed 8 times in 50 mM Tris-citrate buffer pH 7.1 at 2 °C, and frozen 1-14 days. On the day of assay, membranes were washed 4 times in incubation buffer, 20 mM potassium phosphate, pH 7.5 at 25 °C which contained 120 mM potassium chloride unless otherwise indicated.
[3H]muscimol (9.3 Ci/mmol, New England Nuclear) or [3H]GABA (74.5 Ci/mmol, New England Nuclear) binding assays were performed using 5 nM radioligand incubated with washed synaptosomai membranes (ca. 0.5 mg protein) and the test drug in 1 ml volume. Incubations were at 25 °C for 15 min and terminated by rapid centrifugation at 10,000 glS. Non-saturable binding of muscimol was determined using 100/*M muscimoi, and for GABA, using 1 mM GABA.
TBPS binding was studied as described by Supavilai and Karobath 20 using 2 nM [35S]TBPS (69 Ci/ mmol, New England Nuclear) with 200 mM sodium chloride in 50 mM Tris-citrate buffer, pH 7.5, at 23 °C. Non-saturable binding was determined using 100/~M picrotoxinin.
For electrophysiological studies cell cultures were prepared from spinal cords with attached dorsal root ganglia from 12-14-day-old mouse embryos, as described earlier 14 and spinal cord neurones (7-8 weeks in vitro) were penetrated on the modified stage of an inverted phase-contrast microscope, using high resistance (25-40 Mr2) glass micropipettes filled with either 4 M potassium acetate (KAc) or 3 M potassium chloride (KC1). Cultures were bathed in a phosphate buffered saline (composition in raM: NaC1 143.4, KCI 4.2, CaCI2 0.9, MgCI 2 1.0 and glucose 5.6 in 9.5 mM sodium phosphate buffer at pH 7.35-7.40). Using a conventional bridge circuit, simultaneous current injection and membrane potential measurement were made with a single recording micropipette; data were recorded on a 6-channel Gould polygraph.
For determination of spontaeous neuronal activity, spinal cord neurones (at 36 °C) were impaled using KAc-filled electrodes and activity determined over a 3-min period. Normal spontaneous activity consisted of random firing of action potentials with an admixture of excitatory and inhibitory synaptic potentials9. 15 . Following determination of activity in 6-11 'control' cells, drugs were added to the bathing medium and activity determined in a further 4-15 cells.
In iontophoresis experiments, 10 mM MgC12 was added to the bathing medium to suppress spontaneous activity, and the culture temperature was decreased slightly (to 33 °C) to prolong culture viability. GABA (0.5 M, pH 3.2) was applied iontophoretically to spinal cord neurones using 400 ms rectangular current pulses (+0.5 to +20 hA) at 4-s intervals. Drugs or vehicle (0.1% or less dimethyl sulfoxide) were applied by miniperfusion (0.2 psi, 30 s) from a pipette 15-100/~m from the cell soma. Medium containing vehicle only did not alter responses to GABA. GABA responses (KCI recordings) of 6-9 mV amplitude were evoked following membrane hyperpolarization to -80 to -90 mV and were used for assessment of drug actions. Data were accepted only if the amino acid responses returned to control levels within 5 min following removal of the drug-containing pipette from the vicinity of the cell under study. When KAc recording micropipettes were 
TABLE I

Chemical structures and pharmacological properties of the caprolactams studied
Cony, convulsant; Depr, depressant; Lmc, loss of muscle control; Lrr, loss of righting reflex; n.t., not tested. 
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RESULTS
Under the present assay conditions, pentobarbitone stimulated GABA and muscimol binding to rat membranes as previously observed tS. Pentobarbitone was a slightly more potent enhancer of muscimol binding (ECs0 = 336 + 20 ~M) than of GABA binding (ECs0 = 428 + 23/~M) and also produced greater maximal enhancement of muscimol binding at high barbiturate concentrations (Fig. 1 ). In contrast, picrotoxinin inhibited both GABA and muscimol binding. At 1/~M, picrotoxinin inhibited muscimol binding by 15.1% and GABA binding by 14.5%, however, at 100/~M picrotoxinin, muscimol binding was inhibited much more than GABA binding (48.4% compared with 25.7% inhibition). Because of the greater sensitivity of muscimol binding to modulation by barbiturates and picrotoxin, muscimol was used as the radioligand for investigation of caprolactam effects at GABA receptor-ionophore complexes. The structures of the caprolactams studied and their in vivo activities are shown in Table I . The C4 and C6 methyl-substituted caprolactams (A-F) (Table II) inhibited muscimol binding in a concentration-dependent fashion. Compound D was the most potent, significantly inhibited binding at 10/xM. Maximal inhibition by compounds A-D and F was typically 35%; compound E was a less potent inhibitor of muscimol binding (Table II) .
The C7 substituted caprolactams (G-J) (Table  III) The effects of chloride ions were studied upon GABA receptor modulation by picrotoxin, pento- barbitone and certain caprolactams (Table V) were quiescent. In the presence of compound (O), intracellular injection of depolarizing current could still evoke repetitive firing of action potentials. Further, cell membrane potentials were not depolarized in the presence of either caprolactam. It is thus unlikely that the caprolactam effects arise simply from toxicity. Pentobarbitone (500 pM) produced quiescence in all 6 cells studied, as earlier noted 15, while picrotoxin (100 pM) produced paroxysmal depolarizing events in all 4 cells studied.
DISCUSSION
The finding that pentobarbitone enhancement and picrotoxinin inhibition of GABA receptor binding are more pronounced when muscimol rather than GABA is used as the radioligand may suggest that GABA and muscimol interact somewhat differently with GABA receptor-ionophore complexes. While chloride-dependent enhancement of GABA receptor binding has been demonstrated for a variety of labelled GABA receptor ligands 12, full barbiturateconcentration response curves for [3H]GABA and [3H]muscimol binding have not previously been de-231 scribed within the one study. It is possible, however, that the apparent greater maximal enhancement of muscimol binding compared with GABA binding is the result simply of differing fractional binding site occupancies by the two radioligands. However, since pentobarbitone increases the density rather than the affinity of high affinity muscimol or GABA binding under the experimental conditions usedlS, z2 this interpretation is unlikely.
In independent studies Olsen and Snowman tl found that high concentrations of picrotoxin (30 pM) inhibited GABA binding by about 25% while others8, 22 found that similar picrotoxin or picrotoxinin concentrations inhibited muscimol binding by about 50%. We have confirmed these results by performing paired experiments with picrotoxinin on GABA and muscimol binding in several membrane preparations formed on different occasions. Other evidence exists that muscimol and GABA do not label identical populations of sites in brain membranes. Muscimol labels only one subclass of binding sites while GABA labels two populations in washed synaptosomal membranes 16. Unlike pentobarbitone, diazepam was a more potent enhancer of GABA than of muscimol binding. Since pentobarbitone and picrotoxinin are thought to act on or near GABA receptor coupled chloride channels it may be possible that muscimol labels a subclass of GABA receptors closely associated with GABA-coupled chloride channels.
The C4 and C6 methyl substituted caprolactams are potent convulsants (Table I ) and like picrotoxinin inhibited muscimol binding potently, but only partially (Table II) . That the inhibition was partial was confirmed by the observation that 2 mM of compounds (A-F) did not inhibit binding any more than 1 mM of each particular caprolactam. Compounds (D) and (F) are the most potent inhibitors of muscimol binding, while compound (E), a relatively weak convulsant, was a relatively weak inhibitor.
The good quantitative correlation between the effects of the caprolactams on TBPS binding and on muscimol binding in the presence of chloride ions indicate that the caprolactams are influencing binding to GABA agonist recognition sites and to antagonist sites associated with chloride channels in a similar manner. The appreciably greater potency of the caprolactams against TBPS binding indicate a closer association of their direct site of action with the chlo-ride channels than with the GABA agonist recognition sites. Thus the influence of caprolactams on muscimol binding is relatively weak compared to that of direct acting GABA agonists and furthermore requires the presence of chloride ions.
There is a reasonable qualitative correlation between in vivo activity and the nature of muscimol binding modulation for the C7 substituted caprolactams. The convulsant propyl compound (G) inhibited binding, while the depressants (I and J) enhanced muscimol binding. Caprolactam (H), a weak depressant, was inactive at 1 mM. No enhancement of TBPS binding was observed at the single concentration of caprolactam tested, but the caprolactams which enhanced muscimol binding were all relatively weak inhibitors of TBPS binding.
The relationship between behavioural activity and binding was less obvious for the remaining compounds (K-O). Caprolactam (K), a depressant, inhibited binding, but with an amino substituent it is possible that it inhibits binding at the muscimol recognition site. The other compounds had complex in vivo activities, for example compound (O) is a convulsant but produces muscle paralysis at similar doses. This compound however, markedly enhanced GABA binding. With the possible exception of (K) it is unlikely that the caprolactams act directly upon GABA receptor recognition sites. Like picrotoxin and pentobarbitone, the modulatory effects of the convulsant and the depressant caprolactam tested were largely chloride-dependent. The partial nature of inhibition was different from that of bicuculline methochloride (BMC) which fully inhibited muscimol binding. BMC was more potent in the presence of chloride ions, as earlier noted 22, which may suggest that GABA agonists and antagonists interact with GABA recognition sites differently.
The behaviour of the caprolactams in the electrophysiological assays corresponded to their behaviour in the binding assays. Compound (D), which showed picrotoxin-like inhibition of muscimol and TBPS binding, inhibited GABA responses on spinal cord neurones in culture and produced spontaneous paroxysmal depolarizing events. In contrast, compound (O), which enhanced muscimol binding without influencing TBPS binding, enhanced GABA responses and like pentobarbitone produced quiescence in spinal cord neurones. Unfortunately, due to vehicle sensitivity of the electrophysiological assays, the effects of caprolactam with clear depressant activity in vivo (such as I or J) could not be investigated. Earlier studies using extracellular recording from the substantia nigra in vivo had demonstrated GABA antagonist activity for compounds (B) and (C), following intravenous injection 7 however the site of action of the caprolactams could not be determined in that study. The caprolactams appear to be relatively selective in that compounds (C), (G) and (K) (100/.tM) did not inhibit the uptake of GABA on L-glutamate by rat brain slices (Johnston, unpublished) although some caprolactams at high concentrations inhibit the binding of diazepam to brain membranes (Davies and Skerritt, unpublished).
For the relatively simple C4 and C6 methyl substituted and C7 alkyl substituted caprolactams (A-J)
there appears to be a direct relationship between their behavioural effects (convulsant or depressant) and their effects upon muscimol binding (inhibition or enhancement). This is in contrast to barbiturate effects upon GABA binding. While a correlation between relative anaesthetic potency and relative GABA binding enhancement exists for sedative barbiturates ~8, both sedative and convulsant barbiturates enhance GABA bindingll, Js.25. The relatively simple caprolactam molecular structure may provide another useful too! for the investigation of GABAcoupled channels and their modulation.
